Kap, Jan. 14 -- Seok Yang, CEO of Macrogen has announced that the company has signed a strategic License and Supply Agreement with Thermo Fisher Scientific. The agreement, which was recently signed, aims to expand the global market for Capillary Electrophoresis Sequencing (CES) service.

Macrogen is a precision medicine and biotechnology company based in South Korea. Thermo Fisher Scientific is a leading bioscience corporation employing more than 70,000 workers globally and earning upwards of $24 billion in annual revenues.

CES, a first-generation base sequence analysis method, accurately reads targeted pieces of genetic data. Recent developments in CES technology have increased the popularity of related applications and the growth rate ...